Biocause Pharma(SZ:000627) Zheng Quan Zhi Xing·2025-07-10 16:21Core Viewpoint - The company, Tianmao Industrial Group Co., Ltd., is facing regulatory scrutiny due to failure to timely disclose financial reports, leading to a risk of delisting from the Shenzhen Stock Exchange [1][2]. Group 1: Stock Trading and Regulatory Actions - The company's stock experienced abnormal trading fluctuations, with a cumulative closing price drop exceeding 12% over three consecutive trading days from July 8 to July 10, 2025 [2]. - The China Securities Regulatory Commission (CSRC) issued a notice of investigation on May 6, 2025, due to the company's failure to disclose periodic reports as required by law [1][2]. - Following the investigation, the company was suspended from trading for two months starting May 6, 2025, and resumed trading on July 8, 2025, under a delisting risk warning [1][2]. Group 2: Disclosure and Corporate Governance - The company's board confirmed that aside from the delayed disclosure of the 2024 annual report and the 2025 first-quarter report, there are no other undisclosed significant matters that should be reported according to the Shenzhen Stock Exchange's regulations [2]. - The board has not been made aware of any other information that could significantly impact the trading price of the company's stock or its derivatives that has not been disclosed [2].